ARROWHEAD PHARMACEUTICALS, INC. (ARWR) Scorecard
- 2026-Q2: Total return Win; Revenue growth Win; EPS growth Win.
- 2026-Q1: Total return Lose; Revenue growth Win; EPS growth Win.
- 2025-Q4: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth Lose.
59/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 9 wins, 3 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q23/3 |
WinARWR / S&P 30.00% / 15.20% |
WinARWR / S&P 16.85% / 15.00% |
WinARWR / S&P 77.17% / 50.40% |
| 2026-Q12/3 |
LoseARWR / S&P -5.56% / -4.33% |
WinARWR / S&P 14.09% / 11.30% |
WinARWR / S&P 54.68% / 27.70% |
| 2025-Q42/3 |
WinARWR / S&P 92.49% / 2.65% |
WinARWR / S&P 43539.24% / 9.00% |
LoseARWR / S&P -129.65% / 13.40% |
| 2025-Q32/3 |
WinARWR / S&P 118.29% / 8.12% |
WinARWR / S&P 23258.15% / 4.61% |
LoseARWR / S&P -98.40% / 13.45% |
| 2025-Q22/3 |
WinARWR / S&P 24.02% / 10.94% |
WinARWR / S&P 2816.21% / 4.83% |
LoseARWR / S&P -72.75% / 10.63% |
| 2025-Q11/3 |
LoseARWR / S&P -32.23% / -4.27% |
WinARWR / S&P 1436.97% / 4.98% |
LoseARWR / S&P -67.22% / 10.57% |
| 2024-Q41/3 |
LoseARWR / S&P -2.94% / 2.41% |
LoseARWR / S&P -98.62% / 5.25% |
WinARWR / S&P 86.28% / 6.15% |
| 2024-Q31/3 |
LoseARWR / S&P -25.47% / 5.89% |
LoseARWR / S&P -98.52% / 5.89% |
WinARWR / S&P 160.94% / 6.11% |
| 2024-Q21/3 |
LoseARWR / S&P -9.13% / 4.28% |
LoseARWR / S&P -92.33% / 5.38% |
WinARWR / S&P 172.51% / 5.12% |
| 2024-Q11/3 |
LoseARWR / S&P -6.54% / 10.56% |
LoseARWR / S&P -87.00% / 5.71% |
WinARWR / S&P 196.50% / 5.59% |
| 2023-Q42/3 |
WinARWR / S&P 13.88% / 11.69% |
LoseARWR / S&P -34.71% / 6.81% |
WinARWR / S&P 88.44% / 7.78% |
| 2023-Q31/3 |
LoseARWR / S&P -24.65% / -3.27% |
LoseARWR / S&P -1.03% / 7.52% |
WinARWR / S&P 14.29% / -5.03% |
| 2023-Q22/3 |
WinARWR / S&P 40.39% / 8.74% |
LoseARWR / S&P 2.51% / 9.50% |
WinARWR / S&P 15.54% / -8.57% |
| 2023-Q11/3 |
LoseARWR / S&P -37.38% / 7.50% |
LoseARWR / S&P 3.56% / 10.77% |
WinARWR / S&P 31.19% / -15.69% |
| 2022-Q43/3 |
WinARWR / S&P 22.72% / 7.56% |
WinARWR / S&P 92.72% / 11.88% |
WinARWR / S&P -16.48% / -17.99% |
| 2022-Q32/3 |
LoseARWR / S&P -6.13% / -4.88% |
WinARWR / S&P 75.89% / 13.47% |
WinARWR / S&P 23.53% / -1.41% |
| 2022-Q22/3 |
LoseARWR / S&P -23.44% / -16.10% |
WinARWR / S&P 132.20% / 13.71% |
WinARWR / S&P 20.33% / 11.04% |
| 2022-Q11/3 |
LoseARWR / S&P -30.63% / -4.60% |
WinARWR / S&P 195.57% / 15.97% |
LoseARWR / S&P 1.87% / 42.23% |
| 2021-Q41/3 |
LoseARWR / S&P 6.20% / 11.03% |
WinARWR / S&P 80.89% / 15.00% |
LoseARWR / S&P 74.26% / 96.40% |
| 2021-Q31/3 |
LoseARWR / S&P -24.62% / 0.58% |
WinARWR / S&P 57.16% / 10.77% |
LoseARWR / S&P 61.90% / 69.42% |
| 2021-Q22/3 |
WinARWR / S&P 24.90% / 8.55% |
LoseARWR / S&P -12.95% / 6.58% |
WinARWR / S&P 392.00% / 51.81% |
| 2021-Q10/3 |
LoseARWR / S&P -13.58% / 6.17% |
LoseARWR / S&P -35.87% / -1.06% |
LoseARWR / S&P -1288.89% / 7.39% |
| 2020-Q41/3 |
WinARWR / S&P 78.19% / 12.15% |
LoseARWR / S&P -51.20% / -3.72% |
LoseARWR / S&P -290.57% / -33.42% |
| 2020-Q30/3 |
LoseARWR / S&P -0.30% / 8.93% |
LoseARWR / S&P -47.87% / -2.04% |
LoseARWR / S&P -221.74% / -27.10% |
| 2020-Q21/3 |
WinARWR / S&P 50.12% / 20.54% |
LoseARWR / S&P -9.58% / -0.46% |
LoseARWR / S&P -154.35% / -27.11% |
| 2020-Q12/3 |
LoseARWR / S&P -54.64% / -19.60% |
WinARWR / S&P 46.61% / 3.47% |
WinARWR / S&P 28.57% / -14.75% |
| 2019-Q42/3 |
WinARWR / S&P 125.09% / 9.07% |
WinARWR / S&P 245.93% / 5.36% |
LoseARWR / S&P -251.43% / 2.99% |
| 2019-Q32/3 |
WinARWR / S&P 6.34% / 1.70% |
WinARWR / S&P 945.67% / 5.02% |
LoseARWR / S&P -204.55% / 0.21% |
| 2019-Q22/3 |
WinARWR / S&P 44.41% / 4.30% |
WinARWR / S&P 905.49% / 6.64% |
LoseARWR / S&P ARWR unavailable / 8.65% |
| 2019-Q12/3 |
WinARWR / S&P 47.75% / 13.65% |
WinARWR / S&P 326.66% / 8.12% |
LoseARWR / S&P ARWR unavailable / 14.29% |
| 2018-Q41/3 |
LoseARWR / S&P -35.21% / -13.52% |
WinARWR / S&P 54.79% / 9.05% |
LoseARWR / S&P ARWR unavailable / 18.23% |
| 2018-Q31/3 |
WinARWR / S&P 40.96% / 7.71% |
LoseARWR / S&P -48.60% / 10.21% |
LoseARWR / S&P ARWR unavailable / 19.06% |
| 2018-Q21/3 |
WinARWR / S&P 88.63% / 3.43% |
LoseARWR / S&P -40.15% / 9.03% |
LoseARWR / S&P ARWR unavailable / 14.46% |
| 2018-Q12/3 |
WinARWR / S&P 95.92% / -0.76% |
WinARWR / S&P 65.52% / 7.68% |
LoseARWR / S&P ARWR unavailable / 12.46% |
| 2017-Q41/3 |
LoseARWR / S&P -15.01% / 6.64% |
WinARWR / S&P 581.95% / 7.03% |
LoseARWR / S&P ARWR unavailable / 13.82% |
| 2017-Q32/3 |
WinARWR / S&P 167.28% / 4.48% |
WinARWR / S&P 19736.49% / 5.68% |
LoseARWR / S&P ARWR unavailable / 17.57% |
| 2017-Q21/3 |
LoseARWR / S&P -12.43% / 3.09% |
WinARWR / S&P 13202.57% / 4.83% |
LoseARWR / S&P ARWR unavailable / 17.74% |
| 2017-Q12/3 |
WinARWR / S&P 19.35% / 6.07% |
WinARWR / S&P 5163.63% / 3.67% |
LoseARWR / S&P ARWR unavailable / 13.32% |
| 2016-Q41/3 |
LoseARWR / S&P -78.91% / 3.82% |
WinARWR / S&P 1656.89% / 2.09% |
LoseARWR / S&P ARWR unavailable / 7.05% |
| 2016-Q31/3 |
WinARWR / S&P 38.16% / 3.85% |
LoseARWR / S&P -58.55% / 0.20% |
LoseARWR / S&P ARWR unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | ARWR total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 302.13% | 20.78% |
| Annualized return | 302.13% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | ARWR total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 29.35% | 83.14% |
| Annualized return | 5.28% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | ARWR total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 1154.82% | 319.30% |
| Annualized return | 28.78% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |